Clinical Trials Browser

Phase 2 × Withdrawn × reparixin × Clear all

NCT05212701 2024-04-30

To Assess Efficacy and Safety of Oral Reparixin in Patients With Fatigue and Locally Advanced / Metastatic Breast Cancer

Phase 2 Withdrawn

Breast Neoplasms, Fatigue